DYADIC INTERNATIONAL INC 8-K

What Happened
Dyadic International, Inc. announced on May 28, 2026 (via a press release furnished on Form 8‑K) that it is collaborating with Scripps Research to develop rapid‑response hantavirus antibodies and vaccines. The release says the work will leverage Scripps’ prior research on Andes, Marburg and Ebola viruses and Dyadic’s C1 protein production platform to enable fast, scalable biologic production.

Key Details

• Filing: Form 8‑K dated May 28, 2026 (Item 7.01 Regulation FD Disclosure); the press release is furnished as Exhibit 99.1.
• Parties: Dyadic International, Inc. and Scripps Research.
• Focus: Rapid‑response development of hantavirus antibodies and vaccines, leveraging prior Andes, Marburg and Ebola research.
• Platform: Project explicitly cites Dyadic’s C1 platform for fast, scalable biologic production.
• Financials/terms: The Form 8‑K/press release does not disclose financial terms, commitments, or specific timelines.

Why It Matters
This filing signals a research collaboration that could advance Dyadic’s biologics pipeline and demonstrates commercial/research interest in its C1 production platform. For investors, the item is notable as a potential validation of Dyadic’s technology and expanded R&D activity, but the company has not reported any financial terms or milestones in this disclosure. Watch for future updates (press releases, clinical progress, or agreements) for material changes that could affect valuation.